Xcout Intel
Imcheck Therapeutics
ImCheck Therapeutics designs and develops next-generation immunotherapeutic antibodies focused on modulating the immune system through the butyrophilin and butyrophilin-like superfamily of checkpoint molecules. The company's pipeline targets treatments for cancer, infectious disease, and autoimmune disease.
Subscribe to see Imcheck Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Imcheck Therapeutics at a glance
Imcheck Therapeutics is a biotechnology company headquartered in France. Xcout tracks 3 named people at Imcheck Therapeutics, including David Loew (CEO, Ipsen).
Imcheck Therapeutics leadership
- David LoewCEO, Ipsen
- Pierre d’EpenouxCEO, ImCheck Therapeutics
- Daniel OliveProf.
Imcheck Therapeutics competitors
A few of Imcheck Therapeutics's closest competitors — see the full list of competitors and alternatives →
Checkmate Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing proprietary technology to stimulate the immune system to combat cancer.
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
Matchpoint Therapeutics Inc. discovers and develops precision small molecule medicines utilizing covalent chemistry and chemoproteomics screening to treat immune diseases. The company leverages proprietary screening technologies and machine learning algorithms to expand the druggable proteome and design covalent drug candidates for patients with serious inflammatory and immune conditions.
Inventisbio is a biopharmaceutical company that focuses on the discovery and development of innovative drugs for major diseases such as tumors, autoimmune diseases, and metabolic disorders. Utilizing an independent research and development platform, the company creates proprietary drug pipelines targeting oncology drivers, kinases, and autoimmune pathways to serve patients globally.
Monocacy Therapeutics Inc. develops artificial intelligence-guided, first-in-class immune medicines designed to restore optimal immune function and patient health. The company utilizes a full-stack, AI-powered immunology platform to discover and develop next-generation immunotherapies for patients.
Get Imcheck Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Imcheck Therapeutics in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access